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Abstract:  Like other pathogens that readily persist in animal hosts, members of the 
Bornaviridae family have evolved effective mechanisms to evade the innate immune 
response. The prototype of this virus family, Borna disease virus employs an unusual 
replication strategy that removes the triphosphates from the 5’ termini of the viral RNA 
genome. This strategy allows the virus to avoid activation of RIG-I and other innate immune 
response receptors in infected cells. Here we determined whether the newly discovered 
avian bornaviruses (ABV) might use a similar strategy to evade the interferon response. We 
found that de novo infection of QM7 and CEC32 quail cells with two different ABV strains 
was efficiently inhibited by exogenous chicken IFN-. IFN- also reduced the viral load in 
QM7 and CEC32 cells persistently infected with both ABV strains, suggesting that ABV is 
highly sensitive to type I IFN. Although quail cells persistently infected with ABV 
contained high levels of viral RNA, the supernatants of infected cultures did not contain 
detectable levels of biologically active type I IFN. RNA from cells infected with ABV failed 
to induce IFN- synthesis if transfected into human cells. Furthermore, genomic RNA of 
ABV was susceptible to 5’-monophosphate-specific RNase, suggesting that it lacks   
5’-triphospates like BDV. These results indicate that bornaviruses of mammals and birds 
use similar strategies to evade the host immune response. 
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1. Introduction 
All successful persisting viruses must possess some efficient means to evade the immune system of 
the host. Infections with Borna disease virus (BDV) result in life-long viral persistence in cells of the 
central nervous system. Hallmarks of BDV persistence are high viral activity and abundant presence of 
viral antigens in infected cells  [1]. These conditions are expected to create a milieu that triggers 
vigorous host cell responses if not actively counteracted by the pathogen. Other persisting RNA 
viruses such as hepatitis C virus face similar difficulties during replication in liver cells which they 
solve with the help of virus-encoding factors that greatly limit the synthesis of type I interferon (IFN) 
(reviewed in  [2,3]). Interestingly, recent studies  [4] indicate that BDV may employ a remarkably 
different strategy for evasion of the antiviral response of the host. 
BDV is highly sensitive to type I IFN in cell culture. Type I was shown to efficiently protect Vero 
monkey cells and primary rat fibroblasts from de novo infection with BDV  [1]. It was further shown 
to lower viral antigen levels in persistently infected cells  [1]. In support of the view that IFN can 
restrict replication of BDV, mouse-adapted BDV was reported to multiply in cultured embryo cells 
derived from type I IFN receptor-deficient but not wild-type mice  [5]. Surprisingly, however, in vivo 
virulence of BDV was not influenced by type I IFN in mice as no substantial differences were noted in 
the kinetics of virus spread in brains of wild-type and type I IFN receptor-deficient mice  [5]. At least 
two different interpretations of these seemingly conflicting results are possible. First, the majority of 
BDV-susceptible cells in the brain may fail to respond to type I IFN. Second, BDV may suppress the 
synthesis of substantial amounts of type I IFN in infected brains. To distinguish between these two 
possibilities, infection studies were performed with transgenic mice that constitutively express an IFN-
 gene in astrocytes. These experiments showed that IFN--transgenic mice were highly resistant to 
BDV infection  [5], strongly arguing in favour of the second possibility. 
How does BDV suppress IFN synthesis? Based on the findings discussed above, BDV could either 
actively block IFN induction pathways of the host or else hide from detection by receptors of the 
innate immune system. Evidence for both scenarios is available. Unterstab and coworkers  [6] found 
that the P protein of BDV can inhibit the activity of TBK1, the principal regulatory kinase that 
activates IRF3 which is required for RIG-I-dependent induction of IFN genes in virus-infected cells. 
These results suggested that BDV-P may act as a decoy target for TBK1. However, this hypothesis 
could not satisfactorily explain why uninfected and persistently infected cells synthesized comparable 
amounts of IFN after infection with other viruses. An alternative scenario was suggested by Habjan 
and coworkers  [4] who found that genomic RNA purified from BDV particles failed to stimulate RIG-
I-dependent IFN synthesis in indicator cells, whereas purified genomic RNA of most other RNA 
viruses readily induced IFN gene expression. Additional studies showed that unlike in the case of 
viruses which are potent inducers of IFN, the 5’ termini of genomic RNA from BDV are not 
triphosphorylated and thus cannot be recognized by RIG-I. Since it was previously demonstrated that 
BDV employs an unusual replication strategy which includes a step that results in the specific   Viruses 2010, 2                                       
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5’ trimming of viral RNA   [7,8], these results suggested that BDV has developed this peculiar 
replication strategy in order to facilitate evasion of the host immune response  [4]. 
Novel BDV-related viruses of birds, designated avian bornaviruses (ABV), were recently 
discovered  [9,10] that cause proventricular dilatation disease in parrots  [9-13] and non-psittacine 
birds  [14]. Immunohistochemical and molecular analysis of organs from diseased birds suggested that 
ABV can replicate in a vast range of different organs and cell types of parrots  [11,13,14]. ABV 
isolates are genetically more diverse than classical BDV and at least five genotypes have been 
identified to date  [9,10,14]. Prototype members of genotypes 2 and 4 were successfully isolated from 
clinical specimens and shown to replicate in QM-7 and CEC32 quail cell lines  [11]. However, no 
information regarding how ABV might cope with the IFN system of avian host cells has to date been 
available.  
2. Results and Discussion 
2.1. Sensitive monitoring of ABV infection using antiserum specific for the viral N protein 
Figure 1. Rabbit antiserum specifically detecting the N protein of ABV in infected cells. 
(A) Indirect immunofluorescence analysis of QM-7 cells infected with ABV strains #6758 
or #6609. Persistently infected and uninfected QM-7 cells were mixed at an initial ratio of 
1:20 before plating. After overnight growth, the cultures were stained with antiserum (red) 
to visualize infected cells. DAPI (blue) was used for counter-staining. (B) Western blot 
analysis of lysates derived from QM-7 cells persistently infected with ABV strains #6758 
or #6609. Uninfected QM-7 cells (0) served as controls. Pre-stained marker proteins (M) 
served as size standards. 
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We previously employed cross-reactive antisera originally made against the N and P proteins of 
BDV to detect the corresponding viral products in ABV-infected quail cells  [11]. To detect ABV 
infections with greater sensitivity, we now generated a new rabbit antiserum that is directed against 
purified, histidine-tagged ABV-N protein (for details see Materials and Methods). When used for 
indirect immunofluorescence analysis of QM-7 quail cells, this new antiserum specifically recognized 
single cells infected with either ABV isolate #6758 (genotype 4) or isolate #6609 (genotype 2) in Viruses 2010, 2                                       
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cultures of mainly uninfected cells (Figure 1A). Western blot analysis of lysates from QM-7 cells 
infected with the two different ABV isolates further showed that the new antiserum specifically 
detected a single viral protein of slightly less than 40-kDa, the predicted size of the translation product 
of the ABV N gene (Figure 1B). Taken together these results demonstrated that the newly generated 
rabbit antiserum represents an invaluable tool for a specific and sensitive detection of ABV-infected 
cells.  
2.2. Type I IFN prevents efficient spread of ABV to uninfected quail cells 
Figure 2. Effect of chicken IFN-α on the de novo infection of QM-7 (A) and CEC32 (B) 
quail cells with ABV strains #6758 and #6609. Virus exposure of uninfected cultures was 
started by mixing persistently infected and uninfected cells at an initial ratio of 1:20. The 
mixed cultures were then plated into two separate dishes which were subsequently kept in 
either plain medium (closed symbols) or medium containing 100 units per ml of chicken 
IFN-α (open symbols). The kinetics of virus spread was measured by visualizing ABV-N-
positive cells in culture samples using indirect immunofluorescence analysis and by 
calculating the percentage of virus-infected cells. 
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To determine if type I IFN would influence the spread of ABV in quail cell cultures, we mixed 
persistently infected and uninfected cells at a ratio of approximately 1:20 before plating in two 
separate dishes. One of these cultures was then maintained in standard growth medium, whereas the 
second culture was maintained in growth medium supplemented with 100 units per ml of chicken IFN-
, which is highly cross-reactive on quail cells  [15]. Each time when the cultures were split, a sample 
was used to determine the proportion of ABV-infected cells in the populations. If no IFN was present 
in the culture medium, the percentage of QM-7 cells containing easily detectable levels of N protein 
increased steadily and reached nearly 100% after approximately two weeks (Figure 2A). By contrast, 
if IFN was present in the culture medium, the percentage of ABV-N-positive cells remained below 
10% during the entire observation period of 15 days (Figure 2A). The growth kinetics of ABV strains 
#6758 and #6609 under these two different culture conditions were not substantially different. A 
similar picture emerged when the protective effect of IFN against ABV strain #6758 was determined Viruses 2010, 2                                       
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in quail CEC32 rather than QM-7 cells (Figure 2B). As in QM-7 cells, exogenously applied IFN 
inhibited the spread of ABV in cultures of CEC32 cells, indicating that ABV is highly sensitive to type 
I IFN. 
2.3. Type I IFN inhibits the activity of ABV in persistently infected quail cells 
We next investigated if type I IFN would also be able to reduce virus activity in persistently 
infected cells. We used persistently infected quail cell cultures in which >85% of individual cells 
contained high levels of ABV-N. At the beginning of the experiment, the cultures were plated into two 
dishes that either contained standard growth medium or growth medium supplemented with 100 units 
per ml of chicken IFN-. As in the previous experiment, samples were analyzed for the presence of 
ABV-N by indirect immunofluorescence when the cultures were split into new dishes. Cultures of 
QM-7 cells persistently infected with ABV strains #6758 or #6609 grown in the absence of IFN 
contained at least 80% ABV-N-positive cells at each time point of analysis (Figure 3A). However, if 
the cultures were grown in IFN-containing medium, the percentage of ABV-N-positive cells declined 
steadily and reached values of about 50% or less after about two weeks (Figure 3A). Similar results 
were obtained if the antiviral activity of type I IFN was measured on CEC32 cells infected with ABV 
strain #6758 (Figure 3B). Thus, type I IFN seems to block a post-entry step of the ABV replication 
cycle. 
Figure 3. Effect of chicken IFN-α on quail cells persistently infected with ABV strains 
#6758 or #6609. Persistently infected QM-7 (A) or CEC32 (B) cells were kept in culture 
medium containing 100 units per ml of chicken IFN-α (open symbols) or plain medium 
(closed symbols). Virus inhibition over time was measured by visualizing ABV-N-positive 
cells in culture samples using indirect immunofluorescence analysis and by calculating the 
percentage of virus-infected cells. 
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2.4. Inefficient activation of type I IFN genes in ABV-infected quail cells 
Since both ABV strains grew well in non-manipulated quail cells but only very poorly in cells that 
were treated with exogenous type I IFN, it appeared likely that ABV is a poor IFN inducer. To directly Viruses 2010, 2                                       
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investigate this possibility, we measured ABV-induced expression of type I IFN genes by two 
independent methods. We first employed a sensitive bioassay  [15] to determine if biologically active 
IFN was secreted by ABV-infected quail cells. These experiments showed that the supernatants of 
ABV-infected CEC32 and QM-7 cells contained extremely low levels of type I IFN that were not 
substantially higher than the background activity observed in uninfected cultures. Control experiments 
in which the influenza virus mutant strain SC35M∆NS1 (which is devoid of the IFN-antagonistic 
factor NS1) was used for IFN induction clearly showed that these cells are capable of synthesizing 
large amounts of type I IFN in response to virus infection (Figure 4A). The view that ABV is an 
extremely poor inducer of type I IFN was confirmed by direct IFN- gene expression analyses by 
Northern blotting (Figure 4B). IFN- mRNA was readily detectable in CEC32 or QM-7 cells infected 
with the positive control virus but not in cells infected with ABV strains #6758 and #6609 (Figure 4B). 
Figure 4. Synthesis of type I IFN by ABV-infected quail cells. (A) Antiviral activity in 
culture supernatants. IFN induction in uninfected cells and in cells persistently infected 
with ABV (strains #6758 and #6609, respectively) were compared (open bars). If the 
uninfected or ABV-infected cell cultures were super-infected with influenza mutant virus 
SC35M∆NS1 for 16 hours (filled bars), IFN was abundantly produced irrespective of 
whether or not the cells were persistently infected with ABV. The combined data from four 
independent experiments are shown. Asterisks indicate samples with IFN titers below the 
detection limit. (B) IFN- transcript levels in the same cultures. After harvesting the 
supernatants, RNA was extracted from the various cultures and IFN- transcript levels 
were determined by Northern blot analysis. RNA from uninfected () or SC35M∆NS1-
infected chicken embryo cells (CEFs) served as positive controls. 
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2.5. Persisting ABV infection does not prevent IFN induction by super-infecting influenza virus  
If ABV encoded a protein that actively inhibits type I IFN induction in infected cells, the response 
to super-infecting viruses should be strongly impaired in ABV-infected cells. To examine this 
possibility we compared uninfected and ABV-infected CEC32 and QM-7 cells with regard to their 
abilities to synthesize type I IFN in response to influenza virus infections. Cultures of ABV-free cells 
infected with SC35M∆NS1 contained about 2,000 units per ml of biologically active IFN (Figure 4A). 
QM-7 cells persistently infected with either ABV strains #6758 or #6609 responded comparably well 
to super-infection with SC35M∆NS1 (Figure 4A). Similarly, no major differences between ABV-
infected and uninfected QM-7 cells were noted if Northern blotting was employed to detect IFN- 
gene expression in response to SC35M∆NS1 infection (Figure 4B). Thus, collectively, these results 
strongly suggested that ABV does not employ an evasion strategy which relies on suppression of IFN 
synthesis by a virus-encoded antagonist.  
2.6. No evidence for triphosphorylated 5’-termini of ABV genomic RNA 
Figure 5. Evasion of host defence by ABV attributed to 5’-monophosphorylated 
genome ends. (A) 293T cells were transfected with total RNA isolated from 
uninfected Vero or QM-7 cells, or from cells infected with RVFV, BDV or ABV, 
respectively. At 8 h post transfection, RNA of the transfected cells was isolated and 
analyzed for IFN-β mRNA induction by qRT-PCR. Values are expressed relative to 
the mock control. Data shown reflect the average of two independent experiments 
with duplicates. (B) RNA isolated from partially purified virus preparations was 
digested at 37° for 30 min with the 5’-monophosphate-specific exonuclease 
Terminator that specifically digests 5’-monophosphorylated but not   
5’-triphosphorylated RNA (+ RNase). An untreated sample (- RNase) served as 
control. Terminator-resistant RNAs in samples from stocks of RVFV, BDV or 
ABV were visualized by RT-PCR analysis using primer pairs specific for the three 
viruses.
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We explored the possibility that ABV and BDV might employ similar hiding strategies to escape 
detection by innate immune receptors. If genomic RNA of ABV lacked terminal 5’-triphosphates as Viruses 2010, 2                                       
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recently reported for BDV  [4], we would predict that RNA from ABV-infected cells fails to trigger an 
IFN response when transfected into suitable host cells. To examine this, total RNA from QM-7 cells 
persistently infected with ABV strain #6758 was prepared and transfected into human 293 T cells. At 8 
h post infection, the transfected cells were lysed, RNA was prepared and IFN- gene induction was 
assessed by quantitative RT-PCR (qRT-PCR). Total RNA from Vero cells infected with either Rift 
valley fever virus (RVFV) or BDV served as positive and negative controls, respectively. We found 
that RNA derived from both ABV- and BDV-infected cells failed to induce substantial levels of IFN- 
mRNA in 293 T cells, whereas RNA from RVFV-infected cells induced the IFN- gene very strongly 
(Figure 5A). 
To determine if genomic RNA extracted from ABV particles lacks terminal 5’-triphosphates like 
BDV, we exposed purified RNA to Terminator exonuclease which specifically degrades 5’-
monophosphorylated RNA and subsequently determined the efficacy of digestion by RT-PCR analysis 
using primer pairs that specifically amplify fragments of the different viral genomes. We observed that 
RNA prepared from ABV or BDV stocks exhibited a high degree of susceptibility to Terminator, 
whereas RNA prepared from RVFV stocks exhibited a high degree of resistance to this exonuclease 
(Figure 5B). These results are compatible with the view that genomic RNA from ABV carries no 5’-
triphosphates which may explain why ABV can infect host cells without triggering a strong IFN 
response. 
3. Experimental Section 
3.1. Viruses 
The isolation of ABV strains #6609 and #6758 was previously described  [11]. Influenza virus 
mutant SC35M-delNS1 was described previously  [16]. RVFV clone 13 and BDV strain He/80FR were 
described previously  [4].  
3.2. Production of antiserum against ABV-N 
Histidine-tagged ABV-N protein was produced in E. coli using expression plasmid pQE9. Protein 
expression was induced with 0.03 mM Isopropyl-β-D-thiogalactopyranosid for 3 h after the bacterial 
culture reached the logarithmic growth phase at 28°C. Bacteria were lysed by sonification and the 
histidine-tagged ABV-N was purified using Ni-Agarose beads (Qiagen), dialysed against PBS for 48 h 
and used for immunization of a rabbit. 
3.3. Cell lines and culture conditions 
Quail cell lines QM-7 and CEC32 persistently infected with ABV strains #6758 or #6609 were 
available  [11]. Both cell lines were cultured with DMEM supplemented with 8% fetal bovine serum, 
2% chicken serum and antibiotics. For virus inhibition studies using chicken IFN-, cells were seeded 
into 6-well dishes in medium supplemented with 100 units per ml of recombinant chicken IFN-α  [17]. 
IFN treatment was continued for 15-18 days. Cultures were split as needed, usually every 3-4 days. 
Vero and HEK 293T cells were cultured with DMEM supplemented with 10% fetal bovine serum and 
antibiotics. Viruses 2010, 2                                       
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3.4. RNA isolation  
RNA from cells or from purified virus was isolated with TriFast reagent (Peqlab) according to the 
manufacturer’s instructions. After addition of glycogen, RNA was precipitated by the addition of 1/10 
volume of 3M sodium acetate and 2.5 volumes of ethanol.  
3.5. Measuring IFN- gene induction after RNA transfection  
HEK 293T cells were transfected with RNA from infected or uninfected cells using Metafectene 
(Biontec) as described in the manufacturer’s protocol. Briefly, 2x10
5 cells per well were seeded into 
12-well tissue culture dishes some 18 h before transfection. RNA samples (1 µg) were diluted in 50 µl 
of OptiMEM (Gibco). In a separate tube, 3 µl of Metafectene was mixed with 50 µl of OptiMEM. 
Solutions containing RNA and Metafectene were then mixed and incubated for 15 min at room 
temperature before being pipetted onto the cells and incubated at 37 °C for 8 h.  
RNA from the transfected HEK 293T cells was isolated using the NucleoSpin RNA II Kit 
(Macherey-Nagel) by following the manufacturer’s protocol. The RNA was eluted in 60 µl of RNase-
free water, and the RNA concentration was determined. RNA samples (1 µg) were used for cDNA 
synthesis with QuantiTect reverse transcription Kit (Qiagen) according to the manufacturer’s 
instructions. IFN-β and γ-actin mRNA levels were analyzed in a LightCycler3 equipment using the 
QuantiTect SYBR Green PCR Kit (Qiagen) and QuantiTect primer sets: QT00996415 and 
QT00203763. 
3.6. Digestion of RNA with 5’-monophosphate specific RNase 
RNA from virus stocks containing RVFV clone 13, BDV strain He/80FR or ABV strain #6758 was 
digested with Terminator (Epicentre) according to the manufacturer’s instructions. For each 
reaction, 0.5 µg of RNA was used. After 30 min incubation at 37 °C the reaction was stopped by 
precipitation of undigested RNA with ethanol. The pellet was re-dissolved in 11 µl of double-distilled 
water and used for cDNA synthesis with RevertAid H Minus First Strand cDNA Synthesis Kit 
(Fermentas) by following the manufacturer’s protocol. For quantification of viral products, 5 µl 
samples of the reverse transcription reactions were subjected to PCR analysis using primers 5’-
gatcagatcaaattagtggc-3’ and 5’-ccaggaacaattaccttg-3’ for ABV, 5’-ttatcaagaagctagtgac-3’ and 5’-
ctctgttccttgttgagg-3’ for BDV, and 5’-gacactcgagttaggctgctgtctttgtaagcctga-3’ and 5’-
gacagacgtctcacatggacaactatcaagagctggcgat-3’ for RVFV. 
3.7. Detection of ABV-infected cells by immunofluorescence analysis 
To determine the percentage of ABV-positive cells in the various cultures, cell samples were seeded 
into 24-well dishes. After overnight growth, the cells were fixed with 3% paraformaldehyde and 
permeabilized with 0.5% Triton X-100. Rabbit antiserum to ABV-N was used typically at 0.1%. 
Bound antibodies were detected with Cy3-conjugated anti-rabbit IgG (Dianova). Cell nuclei were 
counter-stained with DAPI (Hoechst). For calculating the percentage of infected cells, at least 300 
cells were counted. Viruses 2010, 2                                       
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3.8. Detection of ABV-N in QM-7 cell lysates by Western blotting 
For testing the new antiserum by Western blotting, protein samples (10 µg) from infected and 
uninfected QM-7 cells were separated on a 12% SDS gel. After blotting on a PVDF membrane, the 
rabbit anti-serum at 1:500 dilution was applied for 90 min. Bound antibodies were visualized with 
peroxidase-conjugated anti-rabbit IgG (Dianova) and chemiluminescence chemisty (Pierce). 
3.9. Bioassay for type I IFN 
Type I IFN activity in cell culture supernatants was determined using a bioassay that employs quail 
CEC32 cells carrying an IFN-inducible firefly luciferase gene  [15].  
3.10. IFN induction using SC35M-delNS1 
CEC32 or QM-7 cells were infected (multiplicity of infection of 1) with influenza A virus mutant 
(SC35M∆NS1) that lacks the IFN-antagonist factor NS1. After 1 h at room temperature, the virus 
inoculum was removed, fresh DMEM containing 2% fetal bovine serum was added and the cells were 
incubated at 37°C for 16 h.  
3.11. Northern blot analysis 
Cells were lysed with TriFast (Peqlab) and RNA was purified following the manufacturer’s 
protocol. After separation by electrophoresis and blotting on a nylon membrane, IFN transcripts were 
visualized by hybridization with a radioactively labeled chIFN-α1 cDNA probe.  
4. Conclusions 
Our results collectively indicate that the recently discovered avian bornaviruses evade the host IFN 
response by a strategy that resembles the strategy used by classical Borna disease virus, the prototype 
virus of the Bornaviridae family. Both ABV and BDV apparently have acquired mechanisms which 
allow them to hide very efficiently from recognition by innate immune receptors such as RIG-I. 
Presumably as a consequence of this successful hiding strategy which blocks IFN synthesis almost 
completely, neither ABV nor BDV seem to have developed additional mechanisms that would block 
the action of type I IFN in persistently infected cells. 
Interestingly, all available evidence supports the view that bornaviruses do not encode factors 
which might actively repress virus-triggered signaling cascades that lead to the activation of type I IFN 
genes. The evasion strategies of bornaviruses thus differ markedly from strategies used by influenza, 
hepatitis C and other RNA viruses that rely on genes which code for accessory proteins that serve as 
IFN antagonists  [2].  
Circumstantial evidence suggests that the evasion strategy of the bornaviruses is surprisingly 
simple. These viruses trim the 5’ ends of their genomic and anti-genomic RNAs  [8], thereby removing 
any tri-phosphorylated residues which could be sensed by innate immune receptors. It thus appears 
likely that the exceedingly complicated mode of genome replication of bornaviruses  [7] has evolved 
under strong selection pressure from the host innate immune response.  Viruses 2010, 2                                       
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